What I see going forward is Nader’s percentage share of

New Post Public Reply Private Reply Replies (1) Message Board
Goosebumps
628
What I see going forward is Nader’s percentage share of running the company diminishing over time. Nader said around a year ago that he has considered a slower personal roll in the company. Nader said that Dr. Kelly would hire all new employees and further the International Advisory Board. Dr. Kelly has done a wonderful job so far and hit it out of the park with his last few hires.

A great leader is a person that recognizes his weaknesses and hires people to overcome such weaknesses. If you interviewed CEO’s they would tell you that the best things they ever did was to hire the right people and that’s where their success comes from. No one can do it all. Our time as a company with many many employees to do all the needed tasks required to be a big pharmaceutical company is as close as our first approval and revenue. We will grow then for sure.

I would not like to change leadership of Cytodyn at this point in time. It could delay us years and lose the relationships we now share with the FDA. You may not believe that Nader has a great relationship with the FDA but I believe he does. He gives them their due respect and that goes a long way in any relationship. Nader is smart that way.

You can hate or blame Nader all you want. But he has got us this far at a minimal cost and minimal time compared to the averages of biotechs looking for drug approvals. This is the reason we are in the position we are currently. Close to approval. With a change of direction to Covid is and was a huge directional change. Most of and/if not all were NOT supportive of his change of direction.

Fact is we are most likely to get our first approval in Covid. Looks like a genius move now and he took heat for it. Nader has made great decisions in funding and been very respectful of dilution. Great leadership quality is a conservative approach financially. Nader has that. We should be thankful.

I will support a leader like Nader all day long for the above reasons. He has recognized his mistakes and made changes and that is huge also. Nader has all the qualities we need to get us over the finish line. A lot of the items awaiting our finish are just out of our control and anyone’s control. No matter who is CEO. It’s up to the drug to prove itself out and for regulatory agencies to be aware of it. Nader will be there for us to smile and complement the FDA just like a great CEO would be there.

This is why he is the right person for the CEO of Cytodyn now and until he steps back further. There should be no doubt about that. Yet people will push their agenda and try to discredit Nader.

Listen to them and make your own opinion and review the facts about our CEO. I believe you will find far more important reasons to have Nader than to have someone else leading this company. over the finish line. But all opinions do matter. Do a proper pro/con assessment and have your own opinion.
2

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AppLovin Faces Lawsuit: Investor Unrest Unfolds

Updated Category News Views 5

Shaky Ground Beneath AppLovin's Feet Ah, the sweet smell of litigation in the tech space—it’s like déjà vu for seasoned market folks. Here we have AppLovin, nestled comfortably in San Francisco, now eying a saucy class-action lawsuit. We're looking at shareholders taking a firm stance against some arguably misleading claims. We're talking big deals with allegations...

Continue Reading
ACLM and eClinicalWorks Expand Lifestyle Medicine Reach

Updated Category News Views 74

Changing the Game with Lifestyle Medicine When it comes to healthcare, you're always going to have the skeptics grousing about the old ways. But what happens when you take an old idea and turbocharge it with modern tech? That's where the American College of Lifestyle Medicine (ACLM) and eClinicalWorks step in. They’re throwing a new wrench into the electronic health...

Continue Reading
ZBS Group Takes Over Rabinowitz’s CPA Practice with Bold Moves

Updated Category News Views 25

Transitioning Power in the CPA World Let's cut to the chase—when a seasoned CPA like Joseph Rabinowitz picks up the phone to secure a succession partner, it's a big deal. Enter ZBS Group LLP, steered by Michael Zaidman, which isn't a stranger to these waters, undertaking their fourth CPA practice acquisition through Rabinowitz's corner of the accounting universe....

Continue Reading
SWFI's I20 Summit Spotlights 3,000 Promising Start-Ups

Updated Category News Views 42

Spotlight on Emerging Titans: The Future 100 Watchlist The Sovereign Wealth Fund Institute is rattling the investment cages with their latest stunt, the 'Future 100 Watchlist.' Hot off the press, this list is parading nearly 3,000 start-ups that are biting at the heels of future success. It's high stakes and higher hopes between December 11-16 at Miami's I20 Summit, where...

Continue Reading
Artprice Bridges Art and AI Across the Hispanic World

Updated Category News Views 11

A Monumental Launch with Deep Roots I've been around long enough to see all sorts of moves in the art world and the tech world. But what Artprice by Artmarket is pulling off here—it’s a doozy. Thierry Ehrmann’s “Diálogo entre un pensador y la IA” just went live in Spanish, and that’s not some paperback thrill ride. We’re talking about an 1,800-page piece of...

Continue Reading
Tulsa Hosts Gradient's Global Tech and Investment Event

Updated Category News Views 21

Tulsa's New Spotlight: Gradient's CHROMA Event Well, look at Tulsa, becoming the center of the tech and enterprise universe for a day. Gradient is throwing open the doors for its second annual CHROMA event on September 24, 2026. You might scratch your head and say, ‘Tulsa? Really?’ But hear me out—this isn’t just a local shindig. We're talking about a one-day...

Continue Reading
SOPHiA GENETICS' Q3 2026: Revenue Growth & Challenges

Updated Category News Views 7

Unpacking SOPHiA GENETICS' Third Quarter Figures Let's cut through the jargon and get straight to the brass tacks. SOPHiA GENETICS (NASDAQ:SOPH) just posted their third quarter numbers for 2026, and it’s a mixed bag, my friends. Sure, they boasted a 25% bump in revenue, hitting $24.3 million, but the devil's in the details—net losses nudged up to $20.3 million, not...

Continue Reading
Marathon Petroleum's Massive Q3 2026 Profit Surge

Updated Category News Views 13

Marathon's Profit Skyrockets Marathon Petroleum Corp. (NYSE: MPC) just pulled off a Houdini act in the third quarter of 2026, as they reported a staggering net income of $7.4 billion. Compare that to last year's third quarter profits of $1.4 billion, and it's like comparing a sumo wrestler with a featherweight fighter. This transformation isn't just a fluke, it's a result...

Continue Reading
Newcomers, Veterans Elevate NYSE's Tokenization Efforts

Updated Category News Views 89

Breaking New Ground at the NYSE When the bell rings at the NYSE these days, it's not just marking the start of another trading session. It's the sound of change clanging its way onto Wall Street. On November 3, 2026, the NYSE threw its hat deeper into the tokenization ring, a game-changer perhaps. They've roped in some big guns—Securitize, tZERO, Broadridge Financial...

Continue Reading
Illumina's Role in Singapore's Precision Medicine Leap

Updated Category News Views 160

Singapore's Bold Step into Precision Medicine When it comes to revolutionizing healthcare, Singapore isn't content to sit on the sidelines. They've just thrown a serious hat into the ring with the SG-INSIGHT study, a cornerstone of their National Precision Medicine programme. And Illumina, Inc. (NASDAQ:ILMN) is right there in it, gearing up to sequence the genomes of...

Continue Reading

Top 5 Most Recently Viewed Articles

Rising Demand and Technological Advancements in Krill Meal Market

Updated Category News Views 226

Understanding the Expanding Krill Meal Market The krill meal market is undergoing remarkable growth, fueled by a shift in consumer preferences favoring clean-label food products and natural flavor enhancers. According to recent estimates, the market is poised to expand significantly, reaching an impressive valuation by the end of an upcoming decade. This growth can be...

Continue Reading
Tango Therapeutics Begins Dosing in Pivotal Cancer Trial

Updated Category News Views 224

Tango Therapeutics Begins Dosing in Pivotal Cancer Trial BOSTON — Tango Therapeutics, Inc. (NASDAQ: TNGX), a dynamic biotechnology company dedicated to revolutionizing cancer care, has achieved a pivotal milestone by dosing the first patient in its TNG456 Phase 1/2 trial aimed at patients with MTAP-deleted solid tumors, particularly glioblastoma (GBM). Known for its...

Continue Reading
Investors Invited to Explore Class Action against Rentokil Initial

Updated Category News Views 188

Investors Encouraged to Join Class Action Against Rentokil Initial Bronstein, Gewirtz & Grossman, LLC, a well-respected law firm known for its expertise in securities cases, is reaching out to investors of Rentokil Initial Plc. This communication centers around a class action lawsuit that has been filed on behalf of those affected by some significant events concerning the...

Continue Reading
Murphy USA's Dividend Boost: A Commitment to Shareholders

Updated Category News Views 78

Murphy USA's Dividend Boost Reflects Confidence in Growth Murphy USA Inc. (NYSE: MUSA), a well-known player in the gasoline and convenience store sector, has recently announced an increase in its quarterly cash dividend. The company's Board has declared a new dividend of $0.48 per share, which represents a notable 6.7% rise from the previous dividend. This increase...

Continue Reading
Cloudinary Enhances Digital Asset Management with New Features

Updated Category News Views 181

Cloudinary's Innovative Update to Digital Asset Management Today, Cloudinary, the leading image and video platform, revealed significant advancements in its API-first digital asset management (DAM) solution. These enhancements are designed to address the evolving needs of brands in managing their visual assets efficiently and effectively. With a focus on streamlining...

Continue Reading